Trazodone: A 5-Year Review of Antidepressant Efficacy

Schatzberg, Alan F.

doi:10.1159/000284523

Cited by 21 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An interesting observation of our study was the combination of trazodone and SSRI. Although trazodone is an older antidepressant, it has been used more as a sedative hypnotic in recent times [35]. This could explain its relative lack of utility as a combination agent elsewhere.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant Prescribing Patterns for Depressive and Anxiety Disorders in a Singapore Hospital

Soh¹,

Lim

Chan³

et al. 2015

OJPsych

View full text Add to dashboard Cite

Objective: Although antidepressants are the recommended first-line pharmacological treatments for depressive and anxiety disorders, their prescribing patterns have not been studied in Singapore. We investigate antidepressant prescription patterns for outpatients with depressive and anxiety disorders in a general hospital in Singapore. We hypothesize that intolerance to side effects and lack of efficacy may contribute to medication switching, and that initiation of antidepressant therapy is not easily tolerated. Methods: A retrospective review of the casenotes of outpatients was carried out between January 2013 and December 2013. A total of 206 patients were randomly selected. The study was approved by the hospital's institutional review board. Data analysis was carried out using SPSS version 18. Results: There were more females than males (ratio 1.7:1) with a mean age of 50.6 ± 15.2 years. Depressive disorder, comprising 50% of the sample, was the most frequent diagnosis followed by anxiety disorder (27.2%), mixed anxiety-depression (16%) and adjustment disorder (5.8%). Almost all patients (97.1%) were prescribed antidepressants, the most common being selective serotonin reuptake inhibitors (SSRI) (75.5%), followed by the noradrenaline and specific serotonin antidepressant (NaSSA) (13.5%) and tricyclic antidepressants (TCA) (8.5%). Patients prescribed SSRIs tended to be younger and better educated (p = 0.0005). More than half of the patients (52.1%) required antidepressant switching mainly due to lack of efficacy and intolerance of side effects. Combination therapy was prescribed for 17% of patients with SSRI-NaSSA, the most preferred combination. Nearly a quarter (23.8%) patients required augmentation therapy with atypical antipsychotics. Combination (p = 0.024) and augmentation (p = 0.033) were utilized more often for depression than for anxiety disorders. Conclusion: Antidepressant medications are commonly prescribed for depression and anxiety disorders. The main reasons for switching antidepressants were intolerance and lack of efficacy. That about half of the patients reported side effects necessitating medication change confirmed our hypothesis that an-*

show abstract

Section: Discussionmentioning

confidence: 99%

Antidepressant Prescribing Patterns for Depressive and Anxiety Disorders in a Singapore Hospital

Soh¹,

Lim

Chan³

et al. 2015

OJPsych

View full text Add to dashboard Cite

show abstract

“…Administrating trazodone may result in rapid improvement of sleep, reduction of anxiety and restlessness [69]. The antidepressive efficacy was compared to the efficacy of TCA in one the study [70]. Appropriate use of two available forms of trazodone seems to be the key to beneficial use of the substance.…”

Section: Trazodonementioning

confidence: 99%

“…Stosowanie trazodonu może przynieść szybką poprawę snu, zmniejszenie lęku i niepokoju [69]. Skuteczność przeciwdepresyjna w niektórych badaniach jest porównywana do skuteczności TCA [70]. Kluczowe przy stosowaniu tego leku wydaje się umiejętne zastosowanie dwóch dostępnych form substancji -CR (bardziej sedującej w pierwszych godzinach po przyjęciu) i XR (utrzymującej stałe stężenie leku w ciągu doby) [71].…”

Section: Farmakoterapia Depresji -Założenia Ogólneunclassified

Farmakoterapia depresji u pacjentów z zaawansowanymi chorobami

Grabowski¹,

Przybylak²

2019

Palliat Med Pract

View full text Add to dashboard Cite

Sadness and anxiety are natural reactions to approaching death. However, sometimes these symptoms reach the significant intensity and are associated with the development of a depressive episode in people at the end of life. Diagnosis of depression may mean that somatic symptoms of advanced disease are subject to exacerbation due to the mental condition (reduced pain threshold, fatigue, sleep disorders, reduced appetite). Depressive patients will be less likely to cooperate in treatment, which may lead to deterioration of overall health, worse prognosis and higher mortality. It seems, therefore, that pharmacotherapy of depression in end-of-life patients should not be marginalized. However, due to antidepressants' delayed onset of action most patients probably fail to achieve satisfactory improvement on time. We propose as the first target for the treatment of depression in palliative care a fast and safe reduction of symptoms. Without giving up the basic antidepressant treatment, expected risk and benefits should be carefully and individually considered before the inclusion of standard medications, especially in terms of remaining life expectancy. We also believe that, if started, such pharmacotherapy should often be accompanied by medications that can quickly alleviate at least some depression symptoms making it easier for the patient to wait for the beneficial effect of the drug. Focusing on the rapid improvement of mental state, mianserin, mirtazapine, pregabalin, quetiapine, trazodone and vortioxetine seem to be beneficial for use in palliative care. Med Pract 2019; 13, 2: 82-89 Palliat

show abstract

“…Die antidepressive Wirksamkeit von Trazodon wurde durch zahlreiche Studien belegt [Haria et al 1994;Schatzberg 1987;Schuckit 1987;Kane et al 1984;Agnoli et al 1984]. Trazodon scheint auch in der Rezidivprophylaxe wirksam zu sein [Feighner 1986].…”

Section: Trazodon Als Antidepressivumunclassified

Trazodon — ein Antidepressivum mit prosexuellen Eigenschaften

Fritze¹,

Witkowski

1997

Der Urologe B

View full text Add to dashboard Cite

Trazodone: A 5-Year Review of Antidepressant Efficacy

Cited by 21 publications

References 12 publications

Antidepressant Prescribing Patterns for Depressive and Anxiety Disorders in a Singapore Hospital

Antidepressant Prescribing Patterns for Depressive and Anxiety Disorders in a Singapore Hospital

Farmakoterapia depresji u pacjentów z zaawansowanymi chorobami

Trazodon — ein Antidepressivum mit prosexuellen Eigenschaften

Contact Info

Product

Resources

About